Trial NCT01089595

View at ClinicalTrials.gov 
Org. Study IDs: FER-SAR-023

Last trial update was posted on 2017-03-15

MeSH Interventions

Imatinib Mesylate Nilotinib

MeSH Conditions

Neoplasm Metastasis

Other Conditions

GIST Metastatic Disease

Stopping Reasons

Novartis is ending their research program for Nilotinib in GIST.

Limitations And Caveats

Trial ended early due to industry support of provision of nilotinib was discontinued.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID